造血系统包括血液、骨髓、脾脏、淋巴结以及散布于全身各处的淋巴组织和单核-巨噬细胞组织。血液病,即所谓的造血系统疾病,主要表现为周围血细胞成分及功能的变化,以及出凝血机制障碍。尽管目前临床用于治疗血液病的药物种类较多,但大多数缺乏针对性,其疗效与实际需求仍存在一定差距。
中文名称 | 英文名称 | CAS号 | 化学式 | 结构式图片 |
---|---|---|---|---|
双香豆乙酯 | ethyl biscoumacetate | 548-00-5 | C22H16O8 |
|
卡巴克络 | Carbazochrome | 69-81-8 | C10H12N4O3 |
|
华法林钠 | warfarin sodium | 129-06-6 | C19H16O4*Na |
|
华法林 | warfarin | 81-81-2 | C19H16O4 |
|
千金藤素 | cepharanthine | 481-49-2 | C37H38N2O6 |
|
匹卡米隆 | N-nicotinoyl-gamma-aminobutyric acid | 34562-97-5 | C10H12N2O3 |
|
利可君 | leucogen | 1950-36-3 | C14H17NO4S |
|
利伐沙班 | Rivaroxaban | 366789-02-8 | C19H18ClN3O5S |
|
凝血酸 | 4-aminomethyl-cyclohexanecarboxylic acid | 701-54-2 | C8H15NO2 |
|
依度沙班 | edoxaban | 480449-70-5 | C24H30ClN7O4S |
|
伊波格雷 | isbogrel | 89667-40-3 | C18H19NO2 |
|
二甲基丙烯酸氧化锆 | 2-Methylprop-2-enoate;oxozirconium(2+) | 97171-79-4 | C8H10O5Zr |
|
二(D-谷氨酸基-kappaO1)铁水合物(1:1) | Ferrous gluconate hydrate | 299-29-6 | C12H26FeO15 |
|
三甲硅基丙炔醇 | 3-trimethylsilyl-2-propyn-1-ol | 5272-36-6 | C6H12OSi |
|
三氯化铁 | iron(III) chloride | 7705-08-0 | Cl3Fe |
|
丁二酸亚铁 | Iron(II)succinate | 10030-90-7 | C4H6FeO4 |
|
6-氨基己酸 | 6-aminohexanoic acid | 60-32-2 | C6H13NO2 |
|
4-氨甲基苯甲酸 | p-aminomethylbenzoic acid | 56-91-7 | C8H9NO2 |
|
4-[(4-甲基哌嗪-1-基)甲基]苯甲酸二盐酸盐 | 4-[(4-methylpiperazin-1-yl)methyl]benzoic Acid Dihydrochloride | 106261-49-8 | C13H20Cl2N2O2 |
|
4-[(4-甲基-1-哌嗪基)甲基]-N-[6-甲基-5-[[4-(3-吡啶基)-2-嘧啶基]氨基]-3-吡啶基]-3-(三氟甲基)苯甲酰胺 | flumatinib | 895519-90-1 | C29H29F3N8O |
|
2-甲氧基-5-(1-丙烯基)苯酚 | 2-methoxy-5-(1-propenyl)phenol | 501-20-2 | C10H12O2 |
|
2-氧代-4-苯基丁酸乙酯 | 2-oxo-4-phenylbutanoic acid ethyl ester | 64920-29-2 | C12H14O3 |
|
1-环丙基-2-(2-氟苯基)乙酮 | 1-cyclopropyl-2-(2-fluorophenyl)ethanone | 150322-73-9 | C11H11FO |
|
1-[3-氯-5-[[[4-(4-氯-2-噻吩基)-5-(4-环己基-1-哌嗪基)-2-噻唑基]氨基]羰基]-2-吡啶基]-4-哌啶羧酸 | avatrombopag | 570406-98-3 | C29H34Cl2N6O3S2 |
|
—— | ferroheme b | 14875-96-8 | C34H32N4O4*Fe |
|
—— | Injectafer | 9007-72-1 | C24H44FeO25- |
|
—— | heme b | 927179-10-0 | C34H32FeN4O4 |
|
—— | (+/-)-2-(dimethylamino)-1-<<o-(m-methoxyphenethyl)phenoxy>methyl>ethyl hydrogen succinate | 125926-17-2 | C4H6O4*C20H27NO2 |
|
—— | Ferrous Gluconate | 6047-12-7 | C12H22FeO14 |
|
—— | Iron gluconate | 299-29-6 | C12H24FeO14 |
|
—— | Zirconium methacrylate | 84057-81-8 | C16H20O8Zr |
|
—— | Naftazone | 15687-37-3 | C11H9N3O2 |
|
—— | Ferrous lactate | 85993-25-5 | C6H10FeO6 |
|
—— | Unii-mul7onl3Z6 | 1301-70-8 | C8H18Fe2O12P2 |
|
—— | Ferroheme | 14875-96-8 | C34H32FeN4O4 |
|
—— | argatroban | 121785-71-5 | C23H36N6O5S |
|
—— | ferrous succinate | 10030-90-7 | C4H4O4*Fe |
|
—— | 1-Methyl-17β-acetoxy-Δ<sup>1</sup>-5α-androsten | 434-05-9 | C22H32O3 |
|
—— | Argatroban, 21R- | 1379603-43-6 | C23H38N6O6S |
|
—— | 2-methylprop-2-enoic acid;zirconium | 84057-81-8 | C16H24O8Zr |
|
—— | 6132-04-3 | C6H10NaO8 |
|
|
—— | Iron,7,12,17-tetramethyl-8,13-divinyl-2,18-porphinedipropionato(2-)]- | 14875-96-8 | C34H32FeN4O4 |
|
—— | Iron;2,3,4,5,6-pentahydroxyhexanoic acid | 299-29-6 | C12H24FeO14 |
|
—— | (2R,4R)-1-[5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid | 74863-84-6 | C23H36N6O5S |
|
—— | Berbamine (dihydrochloride) | 6078-17-7 | C37H42Cl2N2O6 |
|
—— | ozagrel sodium | 82571-53-7 | C13H11N2O2*Na |
|
—— | 4-((4-methylpiperazin-1-yl)methyl)benzoic acid dihydrochloride | 106261-49-8 | C13H18N2O2*2ClH |
|
—— | Adrenochrom-semicarbazon | 69-81-8 | C10H12N4O3 |
|
—— | warfarin | 129-06-6 | C19H15O4*Na |
|
—— | iron(II) fumarate | 141-01-5 | C4H2O4*Fe |
|